Antihypertensive efficacy of losartan versus olmesartan
Pro Research Analysisby 
Searched over 200M research papers
Comparative Antihypertensive Efficacy: Olmesartan vs. Losartan
Blood Pressure Reduction: Diastolic and Systolic Outcomes
Multiple studies consistently show that olmesartan is more effective than losartan in reducing both diastolic and systolic blood pressure in patients with hypertension. In randomized, double-blind trials, olmesartan at a starting dose of 20 mg once daily produced a significantly greater reduction in sitting diastolic blood pressure (DBP) compared to losartan 50 mg once daily, with reductions of 11.5–13.5 mm Hg for olmesartan versus 8.2 mm Hg for losartan after 8 weeks of treatment. The reduction in systolic blood pressure (SBP) was also greater with olmesartan, though the difference was less pronounced than for DBP 1246+3 MORE.
Ambulatory Blood Pressure Monitoring and 24-Hour Control
Olmesartan demonstrated superior 24-hour blood pressure control compared to losartan. The mean 24-hour DBP reduction was 8.5 mm Hg with olmesartan versus 6.2 mm Hg with losartan, and the mean 24-hour SBP reduction was 12.5 mm Hg with olmesartan compared to 9.0 mm Hg with losartan 12. These findings indicate that olmesartan provides more sustained blood pressure lowering throughout the day.
Goal Attainment: Achieving Blood Pressure Targets
A higher percentage of patients achieved recommended blood pressure goals (<140/90 mm Hg and <130/85 mm Hg) with olmesartan than with losartan. Approximately 50% more patients reached the standard goal and about three times more reached the stricter goal with olmesartan compared to losartan 510. This suggests olmesartan is more effective for helping patients achieve guideline-recommended targets.
Efficacy in Different Patient Populations
Olmesartan’s superior efficacy over losartan was observed in both patients new to antihypertensive therapy and those previously treated with other medications. In both groups, olmesartan led to greater reductions in seated DBP and a higher proportion of patients achieving blood pressure goals .
Meta-Analyses and Broader Comparisons
Meta-analyses and systematic reviews confirm that olmesartan provides greater reductions in both DBP and SBP compared to losartan, with no increase in adverse events. The antihypertensive response rates and safety profiles were similar between the two drugs, but olmesartan consistently achieved better blood pressure control .
Safety and Tolerability
Both olmesartan and losartan were well tolerated across studies, with similar rates of adverse events. No significant safety concerns were identified for either drug, supporting their use in clinical practice 1246+3 MORE.
Conclusion
Olmesartan is consistently more effective than losartan in lowering both diastolic and systolic blood pressure, achieving blood pressure targets, and providing sustained 24-hour control, while maintaining a similar safety profile. These findings support the use of olmesartan as a preferred option for patients requiring effective antihypertensive therapy.
Sources and full results
Most relevant research papers on this topic